Pumping to Up Maternal Milk Production for Preterms (PUMMPP)

July 15, 2026 updated by: Colm Travers, University of Alabama at Birmingham

Pumping to Up Maternal Milk Production for Preterms (PUMMPP)

The goal of this clinical trial is to learn about the effect of breast-pumping frequency on breast milk supply/ volume in mothers of preterm infants. The main question it aims to answer is:

- What effect does pumping frequency have on breast milk supply.

Researchers will compare breastmilk supply of mothers who pump every 2 hours to the supply of those who pump every 3 hours to see if there is a difference in the amount of breastmilk they produce.

Participants will be assigned to either pump every 2 hours or every 3 hours and record how many milliliters of breastmilk they produce daily for the first 28 days of their baby's life.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35249
        • Recruiting
        • University of Alabama Birmingham
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Inborn infants <32 weeks gestation
  • Out-born infants transferred to our facility <48hours of life
  • Infants <1500 grams at birth
  • Infants whose parents/ guardians have provided legal consent for study participation

Exclusion Criteria:

  • Infants with birthing persons' that are severe/critically ill
  • Birthing persons of infants <18 years old
  • Infants with terminal illness or decision to withhold or limit support
  • infants with major congenital anomalies, chromosomal disorders, or congenital infections

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pumping every 2 hours
Mothers of patients in this group will be assigned to pump/ express breastmilk every 2 hours.
The intervention will be pumping every 2 hours.
Other Names:
  • breast pumping every 2 hours
Active Comparator: Pumping every 3 hours
Mothers of patients in this group will be assigned to pump/ express breastmilk every 3 hours.
The intervention will be pumping every 3 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Volume of expressed breastmilk
Time Frame: From enrollment to 28 days of life
The primary outcome measure will be the volume of expressed breastmilk obtained in mL per day in the group pumping every 2 hours compared the group pumping every 3 hours
From enrollment to 28 days of life

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of donor breast milk feedings
Time Frame: From enrollment to 28 days of life
This outcome will assess the percentage of any enteral feeding that is derived from donor breast milk.
From enrollment to 28 days of life
The number of days alive on full feedings
Time Frame: From enrollment to 28 days of life
The total number of days the infant received full enteral feeds (≥120 milliliters(mL)/kilogram(kg)/day).
From enrollment to 28 days of life
The time to full feedings
Time Frame: From enrollment to 28 days of life
The number of days it takes to initially reach full enteral feeds (≥120mL/kg/day)
From enrollment to 28 days of life
The number of infants with clinical evidence of feeding intolerance
Time Frame: From enrollment to first 28 days after birth
Infants that have enteral feeds withheld, or in other words made "nothing by mouth" (NPO) > 24 hours for feeding or abdominal issues
From enrollment to first 28 days after birth
Number of central line days
Time Frame: In the first 28 days of life
The total number of days the infant maintained any type of central line access.
In the first 28 days of life
The number of infants receiving any volume of breastmilk at time of discharge
Time Frame: From enrollment to hospital discharge
Infants who are still receiving any volume of expressed breastmilk upon discharge will be identified and noted.
From enrollment to hospital discharge
The number of infants exclusively feeding breastmilk at discharge
Time Frame: From enrollment to hospital discharge
Whether or not enrolled infants are receiving all their nutrition from their mom's own expressed breastmilk upon discharge will be noted
From enrollment to hospital discharge
Average change in weight
Time Frame: from birth to 36 weeks' corrected gestational age
Changes in weight measured in grams (g) from birth to 36 weeks corrected gestational age
from birth to 36 weeks' corrected gestational age
Average change in length
Time Frame: from birth to 36 weeks corrected gestational age
Changes in length measured in centimeters (cm)
from birth to 36 weeks corrected gestational age
Average change in head circumference
Time Frame: from birth to 36 weeks' corrected gestational age
Change in head circumference measured in centimeters (cm)
from birth to 36 weeks' corrected gestational age
The Bayley Scales of Infant and Toddler Development (BSID)
Time Frame: from 18-26 months of age

The Bayley's cognitive component composite score will be assessed and noted.

The cognitive composite score is determined by comparing the child's performance to a normative age-matched sample defined by the assessment. They are interpreted as follows:

Mean score of 100 (Standard deviation=15) at the 50th percentile signifies mid-average functioning.

Scores below 85 (1 Standard deviation below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Monitoring is recommended, along with advice to parents on techniques to enhance development or referral to a therapist based on the level of impairment.

Score below 70 (2 Standard deviation below the mean), at the second percentile, indicate moderate to severe impairment.

In general, scores falling in the lowest 10th percentile indicate developmental delay.

from 18-26 months of age
The Bayley Scales of Infant and Toddler Development (BSID)
Time Frame: From 18-26 months of age

The Bayley's motor component composite score will be assessed and noted.

The motor composite score is determined by comparing the child's performance to a normative age-matched sample defined by the assessment. They are interpreted as follows:

Mean score of 100 (Standard deviation=15) at the 50th percentile signifies mid-average functioning.

Scores below 85 (1 Standard deviation below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Monitoring is recommended, along with advice to parents on techniques to enhance development or referral to a therapist based on the level of impairment.

Score below 70 (2 Standard deviation below the mean), at the second percentile, indicate moderate to severe impairment.

In general, scores falling in the lowest 10th percentile indicate developmental delay.

From 18-26 months of age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 11, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

October 23, 2024

First Submitted That Met QC Criteria

November 1, 2024

First Posted (Actual)

November 4, 2024

Study Record Updates

Last Update Posted (Actual)

July 16, 2026

Last Update Submitted That Met QC Criteria

July 15, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB-300013718
  • UAB (Other Identifier: UAB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe